Toll Free: 1-888-928-9744

BioLineRx, Ltd. - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

BioLineRx, Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'BioLineRx, Ltd. - Product Pipeline Review - 2015', provides an overview of the BioLineRx, Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioLineRx, Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioLineRx, Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioLineRx, Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BioLineRx, Ltd.'s pipeline products

Reasons to buy

- Evaluate BioLineRx, Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioLineRx, Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioLineRx, Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioLineRx, Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioLineRx, Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of BioLineRx, Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 BioLineRx, Ltd. Snapshot 5 BioLineRx, Ltd. Overview 5 Key Information 5 Key Facts 5 BioLineRx, Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 BioLineRx, Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 BioLineRx, Ltd. - Pipeline Products Glance 12 BioLineRx, Ltd. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 BioLineRx, Ltd. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 BioLineRx, Ltd. - Drug Profiles 15 BL-7040 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 BL-8040 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 (ribavirin + hydroxychloroquine) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 BL-1110 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 BL-5040 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 BL-7060 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 BL-8030 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 BL-9010 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 BL-9020 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CGEN-856 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 BioLineRx, Ltd. - Pipeline Analysis 28 BioLineRx, Ltd. - Pipeline Products by Target 28 BioLineRx, Ltd. - Pipeline Products by Route of Administration 29 BioLineRx, Ltd. - Pipeline Products by Molecule Type 30 BioLineRx, Ltd. - Pipeline Products by Mechanism of Action 31 BioLineRx, Ltd. - Recent Pipeline Updates 32 BioLineRx, Ltd. - Dormant Projects 41 BioLineRx, Ltd. - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 BL-1050 42 BL-1020 42 BL-2030 42 BL-4040 43 BL-4060 43 BL-5020 43 BL-6010 43 BL-6020 43 BL-6031 43 BL-6040 43 BL-7020 44 BL-7030 44 BL-7040 44 BL-7050 44 BL-8010 44 BioLineRx, Ltd. - Company Statement 45 BioLineRx, Ltd. - Locations And Subsidiaries 46 Head Office 46 Other Locations & Subsidiaries 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
BioLineRx, Ltd., Key Information 5 BioLineRx, Ltd., Key Facts 5 BioLineRx, Ltd. - Pipeline by Indication, 2015 7 BioLineRx, Ltd. - Pipeline by Stage of Development, 2015 9 BioLineRx, Ltd. - Monotherapy Products in Pipeline, 2015 10 BioLineRx, Ltd. - Combination Treatment Modalities in Pipeline, 2015 11 BioLineRx, Ltd. - Phase II, 2015 12 BioLineRx, Ltd. - Phase I, 2015 13 BioLineRx, Ltd. - Preclinical, 2015 14 BioLineRx, Ltd. - Pipeline by Target, 2015 28 BioLineRx, Ltd. - Pipeline by Route of Administration, 2015 29 BioLineRx, Ltd. - Pipeline by Molecule Type, 2015 30 BioLineRx, Ltd. - Pipeline Products by Mechanism of Action, 2015 31 BioLineRx, Ltd. - Recent Pipeline Updates, 2015 32 BioLineRx, Ltd. - Dormant Developmental Projects,2015 41 BioLineRx, Ltd. - Discontinued Pipeline Products, 2015 42 BioLineRx, Ltd., Subsidiaries 46



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify